NQO1 and breast carcinoma: Our data also clearly demonstrated that β-lapachone treatment sensitized the radioresistant 231-RR cells (Figure 3B) or Hs578t cells (Figure 3C) toward radiation, suggesting that β-lapachone could be potentially developed as a radiosensitizer in breast cancers with an increased NQO1 activity.